Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Methadone dose at the time of release from prison significantly influences retention in treatment: implications from a pilot study of HIV-infected prisoners transitioning to the community in Malaysia.
Wickersham JA, Zahari MM, Azar MM, Kamarulzaman A, Altice FL. Wickersham JA, et al. Among authors: azar mm. Drug Alcohol Depend. 2013 Sep 1;132(1-2):378-82. doi: 10.1016/j.drugalcdep.2013.01.005. Epub 2013 Feb 13. Drug Alcohol Depend. 2013. PMID: 23414931 Free PMC article.
Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial.
Springer SA, Di Paola A, Azar MM, Barbour R, Biondi BE, Desabrais M, Lincoln T, Skiest DJ, Altice FL. Springer SA, et al. Among authors: azar mm. J Acquir Immune Defic Syndr. 2018 May 1;78(1):43-53. doi: 10.1097/QAI.0000000000001634. J Acquir Immune Defic Syndr. 2018. PMID: 29373393 Free PMC article. Clinical Trial.
Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community: Results From a Double-Blind, Placebo-Controlled Trial.
Springer SA, Di Paola A, Barbour R, Azar MM, Altice FL. Springer SA, et al. Among authors: azar mm. J Acquir Immune Defic Syndr. 2018 Sep 1;79(1):92-100. doi: 10.1097/QAI.0000000000001759. J Acquir Immune Defic Syndr. 2018. PMID: 29781884 Free PMC article. Clinical Trial.
Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.
Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Price CC, et al. Among authors: azar mm. Chest. 2020 Oct;158(4):1397-1408. doi: 10.1016/j.chest.2020.06.006. Epub 2020 Jun 15. Chest. 2020. PMID: 32553536 Free PMC article.
138 results